Health is a Political Choice: Global Leaders Call for Shared Responsibility at the World Health Summit, Gallup and GPMB Release Landmark Reports on Emotional Wellbeing and Pandemic Preparedness
mehr
Storys zum Thema Study
Vodafone Institut für Gesellschaft und Kommunikation GmbH
Gen Z leads the way on buying refurbished devices
mehrGreen once again recognized as leader for data centers in Switzerland / Green impresses with its strong customer focus, operational excellence and state-of-the-art data centers
mehrSERV Schweizerische Exportrisikoversicherung
International comparison of Swiss Export Risk Insurance SERV: efficient but operating within a tight legal framework
Zurich (ots) - Swiss Export Risk Insurance SERV had an international benchmarking study carried out. A total of 18 different public export credit agencies (ECAs) were compared on the basis of 20 indicators relating to a range of key areas. SERV scored very highly in the study overall. However, SERV operates within a ...
mehrUniversum Communications Switzerland AG
Universum Swiss Study offer insights from the largest survey capturing trends shaping Switzerland's talent landscape and their most attractive Employers.
Zurich, Switzerland (ots) - Universum, the world's leading provider of talent research and employer branding expertise, is excited to share the latest findings from the largest Talent Survey in Switzerland. Conducted meticulously, the 2025 survey offers unprecedented insights into the preferences and aspirations of ...
mehrswissstaffing - Verband der Personaldienstleister der Schweiz
2Work environment more important than wages - Swiss workers setting new priorities
Ein Dokumentmehr
Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study
Tübingen, Germany (ots) - Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy. Cisplatin is a cornerstone in modern oncology and ...
mehrCanada must reduce reliance on extractive industries and U.S. exports, report finds
Los Angeles/Ottawa (ots) - From dissatisfaction with the Trudeau government to dissatisfaction with Trump’s policies — compounded by general anxiety around tariffs, the economy and a deteriorating relationship with the U.S. — navigating an economic downturn should be an immediate priority for Canada as it heads into a federal election, a new report recommends. In ...
mehrRESULTS OF THE MAIRE FOUNDATION STUDY AT COP29 IN BAKU: PEOPLE IN AZERBAIJAN AND KAZAKHSTAN AWARE OF THE URGENCY OF THE ENERGY TRANSITION
Milan/Baku (ots) - - 55% of Azerbaijani respondents say that the energy transition is a priority, in line with European countries - 64% of Azerbaijani respondents (more than the United Arab Emirates, Saudi Arabia and India) and 53% in Kazakhstan (more than Italy, the United Kingdom, the United States and China ...
mehrGrünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain
Aachen, Germany/Morristown, N.J. (ots) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures ...
mehrswissstaffing - Verband der Personaldienstleister der Schweiz
Swiss Staffingindex: pressure mounts on the labor market
Ein DokumentmehrFirst participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...
mehr
Schweizerischer Nationalfonds / Fonds national suisse
Full-time employees face higher risk of cancer
Bern (ots) - Working at 100% is linked to a higher incidence of the disease, according to an SNSF-funded study. Self-employed men and women who stay at home fared best, but the explanation is not as straightforward as it might seem. Some of the risk factors for cancer are well known - smoking, alcohol, a sedentary lifestyle - while others are a bit harder to explain. For example, work. As part of the completed, ...
mehrTunisia's struggling economy puts democracy at risk, study finds
mehrAcousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming conferences
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR clinical study at the HansonWade 4th Inner Ear Disorders Therapeutics Summit in Boston (MA) from August ...
mehr- 2
Green named leading provider of data center services, for 5th consecutive year
mehr Next UK government must address 'long-term scars' of Brexit and austerity – study
mehrNextGen Industry: Bilaterals III and the role of artificial intelligence - focus topics for the 17th Swissmem Industry Day
Zurich (ots) - More than 1,000 leaders from industry, politics and science accepted the invitation to the Swissmem Industry Day at Kursaal Bern. On this key occasion for the Swiss tech industry, Swissmem President Martin Hirzel called for a return to a pragmatic economic policy in order to address the formation of ...
mehr
swissstaffing - Verband der Personaldienstleister der Schweiz
Wake-up call: Workers want more flexibility in their jobs
Ein DokumentmehrHearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The PROHEAR-Study is a placebo-controlled, Phase 2a study with split-body design, which investigates the otoprotective efficacy ...
mehrParents Show High Satisfaction with Globegarden Childcare Services
Zürich (ots) - Globegarden, a leading provider of childcare in Switzerland, is pleased with the excellent results of a recent parent survey. An impressive 95% of the surveyed parents indicated they would unreservedly recommend Globegarden. The survey involved about 2,000 parents. The parents particularly praised the educational teams' expertise, the quality of ...
mehrSWI swissinfo.ch reaffirms its commitment to reader trust and quality
mehrSchweizerischer Nationalfonds / Fonds national suisse
2Do bacteria make you fat? Prizewinner Maria Luisa Balmer is looking for answers
mehrHearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and European meetings in August and September
Tübingen, Germany (ots) - Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late preclinical stage ACOU082 — during four presentations at industry and research meetings from August 29 to September 5. From August 29–31, Acousia ...
mehr
swissstaffing - Verband der Personaldienstleister der Schweiz
The labor market: Temporary work helps integrate the unemployed into the labor market and provides social security for flexible workers
2 DokumentemehrSchweizerischer Nationalfonds / Fonds national suisse
Obstacles slow down birds tracking global warming
mehrSERV Schweizerische Exportrisikoversicherung
Swiss Export Risk Insurance SERV creates and preserves jobs in Switzerland
Zurich (ots) - Swiss Export Risk Insurance SERV conducted a study on the export and employment effects it generates with Offenburg University's Institute for Trade and Innovation (IfTI). The analysis shows that SERV compensates for exporting and financing risks on a large scale, thus creating and preserving up to 21,000 jobs in Switzerland. SERV also makes additional ...
mehrDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCiTM STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and treatment of ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
Inertial sensors: strength in numbers
mehrswissstaffing - Verband der Personaldienstleister der Schweiz
Temporary work comprehensively protects people in flexible working models against social risks
Ein Dokumentmehr
123456Nächste